Phaseline

Companies › Synthekine

Synthekine: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 5 Phase 1; Oncology, Immunology; next expected readout Apr 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
STK-009
human orthogonal IL-2 cytokine selective for hoRb-expressing CAR-T cells
IL2RAPhase 1Systemic Lupus Erythematosus; CLL/SLLApr 2028
SYNCAR-001
autologous CD19-targeted CAR-T cell with hoRb co-expression
–Phase 1Systemic Lupus Erythematosus; CLL/SLLApr 2028
STK-012
Engineered Interleukin-2 (IL-2) selective for antigen-activated T cells
IL2Phase 1Advanced Solid TumorJan 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06544330SYNCAR-001Phase 1Systemic Lupus ErythematosusImmunologyApr 2028
NCT06544330STK-009Phase 1Systemic Lupus ErythematosusImmunologyApr 2028
NCT05665062SYNCAR-001Phase 1CLL/SLLOncologyJun 2028
NCT05665062STK-009Phase 1CLL/SLLOncologyJun 2028
NCT05098132STK-012Phase 1Advanced Solid TumorOncologyJan 2029

Targets

IL2 (1) IL2RA (1)

Companies with the same targets

Nektar Therapeutics Regeneron Pharmaceuticals Innovent Biologics (Suzhou) AstraZeneca Medicenna Therapeutics Coya Therapeutics HCW Biologics Asher Biotherapeutics Salspera Iovance Biotherapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.